160 related articles for article (PubMed ID: 11880472)
61. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
[TBL] [Abstract][Full Text] [Related]
62. BRAF, K-ras and BAT26 mutations in colorectal polyps and stool.
Jin YM; Li BJ; Qu B; Du YJ
World J Gastroenterol; 2006 Aug; 12(32):5148-52. PubMed ID: 16937524
[TBL] [Abstract][Full Text] [Related]
63. Non-invasive screening for colorectal cancer in Asia.
Chiu HM; Chang LC; Hsu WF; Chou CK; Wu MS
Best Pract Res Clin Gastroenterol; 2015 Dec; 29(6):953-65. PubMed ID: 26651256
[TBL] [Abstract][Full Text] [Related]
64. Improving the effectiveness of fecal occult blood screening for colorectal cancer.
Bond JH
J Natl Cancer Inst; 1999 Oct; 91(19):1602-3. PubMed ID: 10511580
[No Abstract] [Full Text] [Related]
65. Beyond KRAS: a new approach in metastatic colorectal cancer.
Winder T; Lenz HJ
Lancet Oncol; 2010 Aug; 11(8):706-7. PubMed ID: 20619738
[No Abstract] [Full Text] [Related]
66. Molecular stool screening for colorectal cancer.
Mak T; Lalloo F; Evans DG; Hill J
Br J Surg; 2004 Jul; 91(7):790-800. PubMed ID: 15227685
[TBL] [Abstract][Full Text] [Related]
67. Stool screening for colorectal cancer: molecular approaches.
Osborn NK; Ahlquist DA
Gastroenterology; 2005 Jan; 128(1):192-206. PubMed ID: 15633136
[TBL] [Abstract][Full Text] [Related]
68. Noninvasive DNA methylation biomarkers in colorectal cancer: A systematic review.
Xue M; Lai SC; Xu ZP; Wang LJ
J Dig Dis; 2015 Dec; 16(12):699-712. PubMed ID: 26565661
[TBL] [Abstract][Full Text] [Related]
69. Flexible sigmoidoscopy to prevent colorectal cancer.
Jansen JB
Lancet; 2010 Sep; 376(9744):870-1; author reply 871-2. PubMed ID: 20833295
[No Abstract] [Full Text] [Related]
70. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
[TBL] [Abstract][Full Text] [Related]
71. [Genetic changes in colorectal cancer].
Hibi K; Nakao A
Nihon Rinsho; 2003 Sep; 61 Suppl 7():77-80. PubMed ID: 14574859
[No Abstract] [Full Text] [Related]
72. Less is more: not "going the distance" and why.
Harris R; Kinsinger LS
J Natl Cancer Inst; 2011 Dec; 103(23):1726-8. PubMed ID: 22076286
[No Abstract] [Full Text] [Related]
73. On the sensitivity of fecal occult blood test screening for colorectal cancer.
Lang CA; Ransohoff DF
J Natl Cancer Inst; 1997 Oct; 89(19):1392-3. PubMed ID: 9326904
[No Abstract] [Full Text] [Related]
74. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
[TBL] [Abstract][Full Text] [Related]
75. Genetic changes associated with colon tumor development.
Mecklin JP; Peltomäki P
Ann Chir Gynaecol; 2000; 89(3):211-5. PubMed ID: 11079790
[No Abstract] [Full Text] [Related]
76. Genetic and epigenetic marker-based DNA test of stool is a promising approach for colorectal cancer screening.
An SW; Kim NK; Chung HC
Yonsei Med J; 2009 Jun; 50(3):331-4. PubMed ID: 19568592
[TBL] [Abstract][Full Text] [Related]
77. Quantification and integrity analysis of DNA in the stool of colorectal cancer patients may represent a complex alternative to fecal occult blood testing.
de Kok JB
Clin Chem; 2003 Dec; 49(12):2112-3. PubMed ID: 14633900
[No Abstract] [Full Text] [Related]
78. High-resolution melting assay (HRMA) is a simple and sensitive stool-based DNA Test for the detection of mutations in colorectal neoplasms.
Li BS; Wang XY; Xu AG; Ma FL; Ma QY; Li Z; Liu JH; Gan AH; Yu ZJ; Zhang XH; Jiang B
Clin Colorectal Cancer; 2012 Dec; 11(4):280-90. PubMed ID: 22609129
[TBL] [Abstract][Full Text] [Related]
79. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer.
Tortola S; Marcuello E; González I; Reyes G; Arribas R; Aiza G; Sancho FJ; Peinado MA; Capella G
J Clin Oncol; 1999 May; 17(5):1375-81. PubMed ID: 10334521
[TBL] [Abstract][Full Text] [Related]
80. Limitations in molecular detection of lymph node micrometastasis from colorectal cancer.
Klebig F; Fischer C; Petri S; Gerull H; Wagener C; Tschentscher P
Diagn Mol Pathol; 2007 Jun; 16(2):91-5. PubMed ID: 17525678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
